Relative and absolute cancer risks among Nordic kidney transplant recipients—a population-based study

Research output: Contribution to journalJournal articleResearchpeer-review

  • Henrik Benoni
  • Sandra Eloranta
  • Dag O. Dahle
  • My H.S. Svensson
  • Arno Nordin
  • Jan Carstens
  • Geir Mjøen
  • Ilkka Helanterä
  • Vivan Hellström
  • Gunilla Enblad
  • Eero Pukkala
  • Sørensen, Søren Schwartz
  • Marko Lempinen
  • Karin E. Smedby

Kidney transplant recipients (KTRs) have an increased cancer risk compared to the general population, but absolute risks that better reflect the clinical impact of cancer are seldom estimated. All KTRs in Sweden, Norway, Denmark, and Finland, with a first transplantation between 1995 and 2011, were identified through national registries. Post-transplantation cancer occurrence was assessed through linkage with cancer registries. We estimated standardized incidence ratios (SIR), absolute excess risks (AER), and cumulative incidence of cancer in the presence of competing risks. Overall, 12 984 KTRs developed 2215 cancers. The incidence rate of cancer overall was threefold increased (SIR 3.3, 95% confidence interval [CI]: 3.2–3.4). The AER of any cancer was 1560 cases (95% CI: 1468–1656) per 100 000 person-years. The highest AERs were observed for nonmelanoma skin cancer (838, 95% CI: 778–901), non-Hodgkin lymphoma (145, 95% CI: 119–174), lung cancer (126, 95% CI: 98.2–149), and kidney cancer (122, 95% CI: 98.0–149). The five- and ten-year cumulative incidence of any cancer was 8.1% (95% CI: 7.6–8.6%) and 16.8% (95% CI: 16.0–17.6%), respectively. Excess cancer risks were observed among Nordic KTRs for a wide range of cancers. Overall, 1 in 6 patients developed cancer within ten years, supporting extensive post-transplantation cancer vigilance.

Original languageEnglish
JournalTransplant International
Volume33
Issue number12
Pages (from-to)1700-1710
Number of pages11
ISSN0934-0874
DOIs
Publication statusPublished - 2020

Bibliographical note

Publisher Copyright:
© 2020 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT

    Research areas

  • cancer, incidence, malignancy, risk, transplantation

ID: 269496467